TNXB and ovarian serous adenocarcinoma: When the high-grade serous ovarian cancer group was compared to the combined control, there was a significantly larger amount of tenascin-X in serum of patients with high-grade serous ovarian cancer compared to healthy patients (Student's t value of 0.005, Figure 2).